Healthcare entity

FARAPULSE PFA

Technology

All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Boston Scientific Corporation, the most common co-covered peer. We currently track 1 Healthcare story that mention FARAPULSE PFA, all published on March 23, 2026.

Last mentioned: Mar 23, 2026

RSS updates
Share

Entity pulse

Recent coverage · FARAPULSE PFA

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about FARAPULSE PFA

All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Boston Scientific Corporation, the most common co-covered peer. We currently track 1 Healthcare story that mention FARAPULSE PFA, all published on March 23, 2026. Each carries 2 original sources on average.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 14 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering FARAPULSE PFA. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Litigation Notice

    Pomerantz LLP issues first public alert regarding the class action filing against Boston Scientific.

  2. Form 8-K Filing

    BSX files notice with the SEC regarding 'Other Events' involving executive shifts and operational updates.

  3. Q4 2025 Earnings

    Company reports financial results and provides updated guidance on clinical timelines.

  4. AVANT GUARD Trial Pause

    Boston Scientific announces a pause in its FARAPULSE PFA trial, citing the need for data review.

Stories mentioning FARAPULSE PFA 1

Medical Devices Neutral

Boston Scientific Faces Class Action Scrutiny Over Alleged Disclosure Failures

Pomerantz LLP has initiated a class action investigation and filing against Boston Scientific Corporation (BSX), alleging the medical device giant made misleading statements regarding its clinical trials and business prospects. The litigation follows a period of heightened volatility for the company's cardiovascular portfolio, specifically concerning the FARAPULSE PFA system and recent trial adjustments.

2 sources

FARAPULSE PFA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.